Cytek Biosciences shares rise 10.64% premarket on strong preliminary Q4 revenue growth of 8% Y/Y and 19% Q/Q.

Cytek Biosciences (CTKB) rose 10.64% in premarket trading following the announcement of preliminary fourth-quarter and full-year 2025 revenue results. The company reported Q4 2025 revenue of $62 million, reflecting an 8% year-over-year increase and 19% growth from Q3 2025. Strong performance in Services, Reagents, and Asia Pacific instrument sales, coupled with a return to positive instrument growth in EMEA, underscored the results. CEO Wenbin Jiang highlighted these trends as evidence of sustained momentum and confidence in future profitability. The news, combined with the company’s upcoming presentation at the J.P. Morgan Healthcare Conference, likely fueled investor optimism. The premarket surge aligns with the positive revenue guidance and strategic positioning in the flow cytometry market.